Table 2: Recommended Dose Modifications of Doxorubicin Hydrochloride Liposome Injection for Toxicity When Administered in Combination With Bortezomib (PDF/132.9 KB) (PDF/132.12 KB)

Reduce doxorubicin hydrochloride liposome injection for serum bilirubin of 1.2 mg/dL or higher.Acute overdosage with doxorubicin hydrochloride causes increased risk of severe mucositis, leukopenia, and thrombocytopenia.Doxorubicin hydrochloride liposome injection is doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, that is encapsulated in pegylated liposomes for intravenous use. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.

Doxorubicin consists of a naphthacenequinone nucleus linked through a glycosidic bond at ring atom 7 to an amino sugar, daunosamine. Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.. oxorubicin Hydrochloride Liposome Injection + Bortezomib “Hazardous Drugs”, OSHA, http://www.osha.gov/SLTC/hazardousdrugs/index.htmlDoxorubicin hydrochloride liposome injection is a sterile, translucent, red liposomal dispersion in 10 mL or 25 mL glass, single-dose vials.

Patients With Refractory or Intolerant AIDS-Related Kaposi’s Sarcoma (n=74 Total Patients With AIDS-Related Kaposi’s Sarcoma (n=720Table 6: Non-Hematologic Adverse Reactions Reported in ≥ 5% of Patients With AIDS-Related Kaposi’s Sarcoma (PDF/149.99 KB) (PDF/130.46 KB) (PDF/155.64 KB) (PDF/131.11 KB)

Pregnancy: Doxorubicin is classed as FDA Pregnancy Category D.24 There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. Discontinue doxorubicin hydrochloride liposome injection infusion for serious or life-threatening infusion-related reactions Table 1: Recommended Dose Modifications for Hand-Foot Syndrome, Stomatitis, or Hematologic Adverse Reactions

(PDF/88.51 KB) (PDF/132.77 KB) (PDF/86.9 KB) Liposomal doxorubicin Caelyx/Doxil ® was studied for clinical use in the treatment of refractory Kaposi's sarcoma and ovarian cancer. (PDF/130.91 KB) It is used: After surgery to remove the primary tumor in women whose cancer has spread to the lymph nodes under the arm. Table 4: Non-Hematologic Adverse Reactions in Trial 4 (PDF/131.11 KB)

Include prior use of other anthracyclines or anthracenediones in calculations of cumulative dose. (PDF/136.42 KB) (PDF/131.11 KB) (PDF/161.01 KB) (PDF/87.71 KB) The chemical name of doxorubicin hydrochloride is (8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride. Table 3: Hematologic Adverse Reactions in Trial 4